TransMedics Group, Inc. (TMDX) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for TransMedics Group, Inc. (TMDX): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 58/100 — a percentile rank of TransMedics Group, Inc.’s fundamentals against Manufacturing peers, weakest on valuation. A quality ranking, not a price prediction.
| Market cap | $2.7B |
| P / E | 18.0× |
| P / S | 4.1× |
| EV / EBITDA | 26.4× |
| Gross margin | 58.7% |
| Operating margin | 12.2% |
| Net margin | 22.7% |
| Return on equity | 29.3% |
| ROIC | 18.8% |
| Revenue growth | 25.8% |
| Debt / equity | 1.7× |
| Dividend yield | 0.0% |
Is TransMedics Group, Inc. overvalued? P/E looks fair vs its 5-year range; P/S looks undervalued vs its 5-year range; EV/EBITDA looks fair vs its 5-year range; P/B looks undervalued vs its 5-year range.
Independent of the events above — derived from TransMedics Group, Inc.’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact